Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company. The Company is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The Company is focused on progressing Phase III candidates under clinical development Ontinua ER and RVL-1201. It has developed Ontinua ER using its proprietary Osmodex drug delivery system. Ontinua ER has been designated by the FDA as an Orphan Drug in this indication. The Company is conducting a second Phase III clinical trial of RVL-1201 for droopy eyelid. The Company’s promoted products include specialty neurology drugs, such as Lorzone and ConZip for pain management, as well as women's health products, such as Divigel for menopause and the OB Complete family of prescription prenatal dietary supplements. The Company’s non-promoted products portfolio include methylphenidate ER and VERT as well as smaller volume ANDAs and prescription dietary supplements.